Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces AnaptysBio financial results for the three months ended September 30, 2026.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces AnaptysBio financial results for the three months ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Jemperli global sales reached $1.0 billion for nine months, up 29% year over year, supporting royalty growth and long-term collaboration value
- Anaptys receives 12% royalties on annual sales between $1.0 billion and $1.5 billion, with >$390 million annualized royalties targeted by 2029
- Cash and investments fell to $153.0 million from $164.1 million, while remaining royalty monetization debt totaled approximately $270 million
- Litigation post-trial hearing completed October 20, with judgment expected in Q4 2026 or Q1 2027 and Anaptys seeking Jemperli rights reversion
- Continuing-operations income dropped to $3.9 million from $56.3 million, reflecting lower collaboration revenue and $4.8 million litigation costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.